FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

	Check this box if no longer subject to Section 16. Form 4 or Form 5
	Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Instructi	ion 1(b).			Filed		to Section 16(a ion 30(h) of the							4		liouis	per rec		0.5
1. Name and Address of Reporting Person* <u>Kahn Clare</u>				2. Issuer Name and Ticker or Trading Symbol Solid Biosciences Inc. [ SLDB ]							(Che	5. Relationship of Reporting Person(s) (Check all applicable)  X Director 10				to Issuer % Owner		
	TLAND S	*	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/02/2021									Officer (give title below)		Other (specify below)		
STH FLO (Street) CAMBRI		1A	02139		4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Form fi	led by One led by Mor	1				
(City)	(5	State)	(Zip)											Person				
		Tab	le I - Non	-Deriva	ative Se	curities Ac	qui	ired,	Disp	osed o	f, o	r Bene	ficiall	y Owned				
Date		2. Transa Date (Month/D	Execution Date,			Code (Instr. 5)						Form (D) or	rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
					(	Code	v	Amount		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
		-				urities Acq s, warrants								Owned				
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day)	ate, Tr	ransaction of Excode (Instr. Derivative (N		6. Date Exercisable and Expiration Date (Month/Day/Year)			of S Und Der	Title and A Securities derlying rivative Se str. 3 and 4	ecurity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

## **Explanation of Responses:**

\$10.72

1. This option was granted on March 2, 2021 and vests in three equal annual installments on the anniversary of the grant date, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the option will accelerate in full.

Date Exercisable

(1)

Expiration Date

03/02/2031

Title

Common

Stock

## Remarks:

Stock Option

(Right to Buy)

/s/ by Erin Powers Brennan as attorney-in-fact for Clare Kahn

Amount or Number

of Shares

40,000

\$0.00

03/04/2021

40,000

D

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

03/02/2021

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

Α

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(D)

(A)

40,000